Press Releases – Umecrine Cognition

May 27, 2026

Umecrine Cognition presents PBC patient survey data at EASL 2026 revealing central fatigue as the most burdensome symptom

STOCKHOLM – May 27, 2026. Umecrine Cognition today announced new patient survey data confirming that central fatigue, characterized by a loss of self-motivation and cognitive involvement, is the…

Umecrine Cognition will present patient survey data at EASL 2026 suggesting golexanolone addresses critical unmet need in PBC

STOCKHOLM – May 13, 2026. Umecrine Cognition today announced new data from the UK-PBC national cohort, to be presented at the EASL Congress 2026 in Barcelona. The data show that most patients with…

Notice to attend the Annual Shareholders’ Meeting in Umecrine Cognition AB, on May 26, 2026, at 08:30 (am)

The shareholders in Umecrine Cognition AB, reg. no. 556698- 3655, are hereby given notice to attend the annual general shareholders’ meeting at 8:30 a.m. on Thursday 26 May 2026 at the company’s…

Umecrine Cognition presents PBC patient survey data at EASL 2026 revealing central fatigue as the most burdensome symptom

Umecrine Cognition will present patient survey data at EASL 2026 suggesting golexanolone addresses critical unmet need in PBC

Notice to attend the Annual Shareholders’ Meeting in Umecrine Cognition AB, on May 26, 2026, at 08:30 (am)

Viktor Drvota

CEO and Chairman of the Board